Eli Lilly Study Shows Zepbound May Reduce Healthcare Costs
A new real-world study conducted by Eli Lilly shows that patients taking Zepbound, the company's GLP-1 weight-loss medication, experienced significantly lower healthcare costs compared to those not on the drug. After six months, these patients had up to 15% lower medical expenses and after one year, as much as 38%. The study focused on individuals over age 55 with a BMI above 30 or related comorbidities. The findings could help Eli Lilly in its efforts to secure broader insurance coverage for Zepbound. Currently, many patients pay out of pocket due to limited third-party payer support, which has constrained the drug's adoption and revenue potential. If insurers adopt better coverage policies based on this data, it may lead to increased demand and higher sales. Eli Lilly recently reported strong financial results with $23 billion in Q2 revenue driven by robust growth from Mounjaro ($9.9 billion) and Zepbound ($4.9 billion). Despite these successes, the company still faces challenges related to patient access due to high out-of-pocket costs.
Tickers: $LLY
Topics: Eli Lilly GLP-1 drugs healthcare costs insurance coverage Zepbound